caplacizumab

Details

Files
Generic Name:
caplacizumab
Project Status:
Complete
Therapeutic Area:
Acquired thrombotic thrombocytopenic purpura (aTTP)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cablivi
Project Line:
Reimbursement Review
Project Number:
SR0736-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
​Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openMay 09, 2022
Call for patient/clinician input closedJuly 04, 2022
Clarification:

- Patient input submission received from Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation

Submission receivedJune 07, 2022
Submission acceptedJune 21, 2022
Review initiatedJune 22, 2022
Draft CADTH review report(s) provided to sponsor for commentSeptember 07, 2022
Deadline for sponsors commentsSeptember 16, 2022
CADTH review report(s) and responses to comments provided to sponsorOctober 14, 2022
Expert committee meeting (initial)October 26, 2022
Draft recommendation issued to sponsorNovember 07, 2022
Draft recommendation posted for stakeholder feedbackNovember 17, 2022
End of feedback periodDecember 01, 2022
Clarification:

- Reconsideration: major revisions requested by sponsor

Expert committee meetingMarch 22, 2023
Final recommendation issued to sponsor and drug plansApril 05, 2023
Final recommendation postedApril 24, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)April 20, 2023
CADTH review report(s) postedJuly 13, 2023